TP53 and ovarian carcinoma: In conclusion, p53, as a proven immunotherapeutic target in ovarian cancer, plays an important role in the development, progression, and immunotherapy of ovarian cancer and can be modulated by ubiquitination and deubiquitination modifications (Fig. 5B).